Zusammenfassung
Hintergrund
Das Pseudomyxoma-peritonei-Syndrom (PMP) ist eine seltene Erkrankung, bei der die Chirurgie die Grundlage der Behandlung darstellt.
Methode
Übersicht zum aktuellen Behandlungsstandard.
Ergebnisse
Zytoreduktive Chirurgie (CRS) in Kombination mit der hyperthermen intraperitonealen Chemotherapie (HIPEC) bilden die Grundlage der Therapie des PMP. Der Peritonealkarzinoseindex sollte präoperativ anhand der Bildgebung und/oder Laparoskopie bestimmt, intraoperativ validiert und jeweils dokumentiert werden. Eine extraperitoneale Präparation ermöglicht eine weitreichende En-block-Resektion des Peritoneums und der befallenen viszeralen Areale. Die HIPEC sollte mit Mitomycin C über 60–90 min erfolgen. Die vollständige CRS (CC = 0, CC = 1) und der histologische Subtyp sind für die Prognose relevant. Strukturierte Ausbildungsprogramme und Mentoring können die Lernkurve optimieren. Die Nachsorge sollte am operativen Zentrum erfolgen. Nach Ausgangsbildgebung 3 Monate nach CRS sollte in den erst 2 Jahren alle 6 Monate eine Kontrolle erfolgen. Danach können die Intervalle auf 1 Jahr verlängert werden.
Schlussfolgerung
Standardisierung chirurgische Therapie und HIPEC, optimierte Ausbildung und strukturierte Nachsorge am Zentrum führen zu einer hervorragender Langzeitprognose des PMP.
Abstract
Background
Pseudomyxoma peritonei syndrome (PMP) is an orphan disease. Surgery is the fundament of treatment.
Method
Short review summarizing the state of the art treatment.
Results
Cytoreductive surgery (CRS) in combination with hyperthermic intraperitoneal chemotherapy (HIPEC) form the foundations of treatment for PMP. The peritoneal cancer index should be preoperatively determined based on imaging and/or laparoscopy, intraoperatively validated and both should be documented. An extraperitoneal surgical preparation technique leads to effective en bloc resection of the peritoneum and the affected abdominal area. The HIPEC technique should be performed with mitomycin C for 60–90 min. Complete CRS (CC = 0, CC = 1) and the histological subtype are relevant for the prognosis. Structured educational programs and mentoring can optimize the learning curve. The aftercare should be performed at the surgical center. After follow-up imaging at 3 months after CRS, in the first 2 years a control should be carried out every 6 months. Thereafter, the intervals can be extended to 1 year.
Conclusion
Standardized surgical treatment and HIPEC, optimized specific surgical training and structured follow-up at the center lead to an excellent long-term prognosis for patients with PMP.
Literatur
Hinson FL, Ambrose NS (1998) Pseudomyxoma peritonei. Br J Surg 85(10):1332–1339
Smeenk RM, van Velthuysen ML, Verwaal VJ, Zoetmulder FA (2008) Appendiceal neoplasms and pseudomyxoma peritonei: a population based study. Eur J Surg Oncol 34(2):196–201
Lin YL, Xu DZ, Li XB et al (2021) Consensuses and controversies on pseudomyxoma peritonei: a review of the published consensus statements and guidelines. Orphanet J Rare Dis 16(1):85
Sugarbaker PH (2006) New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol 7(1):69–76
Ansari N, Chandrakumaran K, Dayal S, Mohamed F, Cecil TD, Moran BJ (2016) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in 1000 patients with perforated appendiceal epithelial tumours. Eur J Surg Oncol 42(7):1035–1041
Jacquet P, Sugarbaker PH (1996) Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res 82:359–374
Ihemelandu C (2023) The landmark series: scoring systems for primary peritoneal surface malignancy. Ann Surg Oncol 30(3):1832–1837
Yurttas C, Uberruck L, Nadiradze G, Konigsrainer A, Horvath P (2022) Limitations of laparoscopy to assess the peritoneal cancer index and eligibility for cytoreductive surgery with HIPEC in peritoneal metastasis. Langenbecks Arch Surg 407(4):1667–1675
Arjona-Sanchez A, Martinez-Lopez A, Valenzuela-Molina F et al (2022) A proposal for modification of the PSOGI classification according to the Ki-67 proliferation index in pseudomyxoma peritonei. Ann Surg Oncol 29(1):126–136
Campos NMF, Almeida V, Curvo Semedo L (2022) Peritoneal disease: key imaging findings that help in the differential diagnosis. Br J Radiol 95(1130):20210346
Sugarbaker PH (1995) Peritonectomy procedures. Ann Surg 221(1):29–42
Chang KH, Kazanowski M, Staunton O et al (2017) Mentored experience of establishing a national peritoneal malignancy programme—Experience of first 50 operative cases. Eur J Surg Oncol 43(2):395–400
Ansari N, Brown KGM, McBride KE et al (2019) Accelerating the learning curve in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy using an external mentor model. ANZ J Surg 89(9):1097–1101
Parkin E, Selvasekar C, Wilson M, Renehan A, O’Dwyer S, Aziz O (2019) Laparoscopic cytoreductive surgery with hyperthermic Intraperitoneal chemotherapy (L-CRS/HIPEC) for perforated low-grade appendiceal mucinous neoplasm (LAMN II). Ann Surg Oncol 26(7):2285
Wang C, Yin XY, An LB et al (2023) Significance of laparoscopic cytoreductive surgery for appendiceal pseudomyxoma peritonei with limited disease and low tumor burden. Asian J Surg 46(3):1220–1225
Mercier F, Jeremie G, Alyami M et al (2020) Long-term results of laparoscopic cytoreductive surgery and HIPEC for the curative treatment of low-grade pseudomyxoma peritonei and multicystic mesothelioma. Surg Endosc 34(11):4916–4923
Wen HK, Valle SJ, Morris DL (2023) Bromelain and acetylcysteine (BromAc((R))): a novel approach to the treatment of mucinous tumours. Am J Cancer Res 13(4):1522–1532
Ke K, Pillai K, Mekkawy AH et al (2021) The effect of intraperitoneal administration of BromAc on blood parameters: phase 1 study. Discov Oncol 12(1):25
Ahmadi N, Kostadinov D, Sakata S et al (2021) Managing recurrent pseudomyxoma peritonei in 430 patients after complete cytoreduction and HIPEC: a dilemma for patients and surgeons. Ann Surg Oncol 28(12):7809–7820
Chandrakumaran K, Carr NJ, Mohamed F, Cecil TD, Moran BJ (2023) Development and validation of nomograms to predict survival in patients undergoing complete cytoreduction and hyperthermic intraperitoneal chemotherapy for Pseudomyxoma Peritonei of Appendiceal origin. JAMA Surg 158(5):522–530
Govaerts K, Chandrakumaran K, Carr NJ et al (2018) Single centre guidelines for radiological follow-up based on 775 patients treated by cytoreductive surgery and HIPEC for appendiceal pseudomyxoma peritonei. Eur J Surg Oncol 44(9):1371–1377
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
R. Wahba, T. Schmidt, D. Buchner, T. Wagner und C. Bruns geben an, dass kein Interessenkonflikt besteht.
Für diesen Beitrag wurden von den Autor/-innen keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.
Additional information
Redaktion
C. Bruns, Köln
R. Wahba, Köln
QR-Code scannen & Beitrag online lesen
Rights and permissions
About this article
Cite this article
Wahba, R., Schmidt, T., Buchner, D. et al. Chirurgische Therapie des Pseudomyxoma-peritonei-Syndroms – zytoreduktive Chirurgie und hypertherme intraperitoneale Chemotherapie. Chirurgie 94, 840–844 (2023). https://doi.org/10.1007/s00104-023-01937-3
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00104-023-01937-3